Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells $44,623.53 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd Petersen sold 1,737 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $25.69, for a total value of $44,623.53. Following the sale, the director owned 73,794 shares in the company, valued at approximately $1,895,767.86. This represents a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Amphastar Pharmaceuticals Stock Up 1.8%

Shares of AMPH stock opened at $26.07 on Thursday. The stock has a market cap of $1.20 billion, a P/E ratio of 11.54, a price-to-earnings-growth ratio of 7.18 and a beta of 0.91. The company has a debt-to-equity ratio of 0.78, a current ratio of 3.12 and a quick ratio of 2.21. The stock has a fifty day moving average price of $25.52 and a 200 day moving average price of $25.67. Amphastar Pharmaceuticals, Inc. has a one year low of $20.39 and a one year high of $41.13.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.10. Amphastar Pharmaceuticals had a net margin of 15.43% and a return on equity of 19.70%. The company had revenue of $191.84 million during the quarter, compared to analysts’ expectations of $186.90 million. Analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current year.

Analysts Set New Price Targets

AMPH has been the topic of several analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Amphastar Pharmaceuticals in a research note on Monday, December 8th. Needham & Company LLC dropped their price objective on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Bank of America boosted their target price on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 26th. Barclays started coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, December 9th. They set an “equal weight” rating and a $30.00 target price for the company. Finally, Zacks Research lowered shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 14th. Two investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $31.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its position in Amphastar Pharmaceuticals by 7.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,755,665 shares of the company’s stock valued at $46,789,000 after acquiring an additional 128,781 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in shares of Amphastar Pharmaceuticals by 11.5% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,263,598 shares of the company’s stock valued at $36,632,000 after purchasing an additional 130,672 shares during the last quarter. Epoch Investment Partners Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 14.5% in the first quarter. Epoch Investment Partners Inc. now owns 1,261,307 shares of the company’s stock valued at $36,565,000 after purchasing an additional 160,034 shares in the last quarter. Geode Capital Management LLC raised its position in Amphastar Pharmaceuticals by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 973,237 shares of the company’s stock worth $22,348,000 after purchasing an additional 18,161 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in Amphastar Pharmaceuticals by 3.0% during the 3rd quarter. Marshall Wace LLP now owns 874,068 shares of the company’s stock worth $23,294,000 after buying an additional 25,383 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.